Cytopoint vs Apoquel vs Zenrelia vs Befrena vs Numelvi: Which Allergy Medication Is Right for Your Dog?

I watched this conversation play out hundreds of times at the front desk in Albany. The DVM would come out after a skin consult, hand the family a discharge sheet, and say something like “we could try Apoquel, or we could go with Cytopoint.” The family would nod, walk to the car, and Google both from the parking lot.

That was 2017. Today the conversation has three more names in it: Zenrelia, Numelvi, and as of May 2026, Befrena. Five medications, two mechanism classes, and the same family in the same parking lot trying to sort them out.

Five medications, two doors

All five medications control allergic itch, but they reach the itch signal through two different doors. Three are JAK inhibitors: daily pills that block enzymes carrying the itch signal. Two are monoclonal antibodies: injections that neutralize one specific itch-triggering protein. The differences within each group matter as much as the difference between them.

Apoquel (oclacitinib) is a JAK inhibitor, meaning it blocks Janus kinase enzymes that carry the itch signal from the immune system to the skin. Specifically, it targets JAK1. The itch stops fast, usually within four hours. The tradeoff: JAK1 does more than carry itch signals. It's involved in immune surveillance, so blocking it can increase susceptibility to skin infections and, in some dogs, allow subclinical masses to surface. Apoquel has been on the market since 2014, and a ten-year post-market review in JAVMA, the Journal of the American Veterinary Medical Association showed no new safety signals over a decade of widespread use. That's the longest real-world dataset any of these drugs has. Given as a daily tablet. Approximate cost: $60 to $120 per month depending on your dog's weight.

Zenrelia (ilunocitinib) is also a JAK inhibitor, but it was designed for more selective targeting than Apoquel. The clinical pitch is the same itch control with less off-target immune suppression. Early clinical data is encouraging, and the switch conversation usually starts when a dog on Apoquel shows declining neutrophil counts or increasing infection frequency. The limitation is time: Zenrelia doesn't have Apoquel's decade of post-market surveillance data yet. Given as a daily tablet. Pricing is comparable to Apoquel at most clinics.

Cytopoint (lokivetmab) works through a completely different mechanism. It's a monoclonal antibody that targets interleukin-31 (IL-31), one specific cytokine that triggers allergic itch. Because it doesn't suppress the broader JAK pathway, there are fewer reports of immune-related side effects in practice. Given as an injection at the clinic every four to eight weeks. Approximate cost: $50 to $150 per injection depending on dog size. The tradeoff: not every dog responds fully, the effect can fade before the next injection is due, and if your dog's itch involves more than IL-31, Cytopoint alone won't cover it.

Befrena (tirnovetmab) is the second anti-IL-31 monoclonal antibody on the market, this one from Elanco. Same mechanism as Cytopoint: it neutralizes interleukin-31 before it reaches the itch signal. The difference is duration. Elanco's data shows six to eight weeks between injections, compared to Cytopoint's four to eight. Onset is fast, typically within a day. Befrena launched in May 2026, so the post-market dataset is measured in weeks, not years. Given as an injection at the clinic. Cost isn't widely published yet; ask your clinic directly.

Numelvi (atinvicitinib) is the third JAK inhibitor and the newest to market. Where Apoquel blocks JAK1 broadly and catches some JAK3, atinvicitinib was designed for tighter JAK1 selectivity. The clinical pitch: same itch-blocking mechanism, fewer off-target immune effects. FDA approved in late 2025, and it started arriving at vet clinics in spring 2026. The limitation is the same one Zenrelia carries: no multi-year post-market safety data yet. Given as a daily tablet. Pricing varies by clinic; early reports put it in a range similar to Apoquel, but ask your clinic directly.

What about Befrena?

Befrena gets its own section because it arrived in May 2026 and most of the coverage so far is trade press: AAHA conference reports, dvm360, Elanco investor calls. If you've searched “befrena for dogs” and found nothing written for the person who actually owns the dog, that's because almost nothing has been.

Here's what matters if your dog is already on Cytopoint. Both drugs neutralize the same target: interleukin-31. The clinical question is whether Befrena holds longer for your specific dog. Cytopoint's labeled duration is four to eight weeks. Befrena's is six to eight. For a dog whose Cytopoint fades at week three, Befrena might buy an extra two to four weeks per cycle. For a dog whose Cytopoint already lasts seven weeks, the difference is smaller.

Elanco now sells both Zenrelia (the daily oral JAK inhibitor) and Befrena (the injectable anti-IL-31). One company makes a drug for the daily-pill approach and one for the injection approach. If your vet carries Elanco products, both may be available under the same supplier contract.

What we don't have yet: long-term safety data past the initial clinical trials, real-world efficacy across a broad population, and pricing once it settles. The AVMA (the American Veterinary Medical Association) reported on Befrena's approval alongside another biologic for kennel cough prevention. The approval is real. The track record isn't, yet. If your vet suggests trying Befrena, the question worth asking is: what's the plan if it doesn't hold the way the trial data suggests? That conversation matters more than the brochure.

What about Numelvi?

Numelvi gets its own section because when this article first published in May 2026, we got the drug wrong. The original version described Numelvi as an isoxazoline-corticosteroid combination. It isn't. Numelvi is atinvicitinib, a second-generation JAK1 inhibitor. We corrected the article in June 2026. The mistake is worth naming because it shows how thin the consumer-facing information still is for this drug.

Here's what matters if your dog is already on Apoquel or Zenrelia. All three are JAK inhibitors. Apoquel was first, and the ten-year JAVMA review gives it the deepest safety record of any allergy drug on this list. But Apoquel's inhibition is broad. It hits JAK1 and some JAK3, which is why some dogs develop recurring infections or bloodwork shifts over time. Zenrelia was designed for better selectivity. Numelvi pushes that selectivity further, targeting JAK1 more narrowly than either predecessor.

VCA published a consumer-facing monograph on atinvicitinib in spring 2026. That's notable: it means clinics are prescribing it and owners are asking about it. On Reddit, owners who've switched from Apoquel report early positive results. One wrote that her dog had been on Apoquel and Cytopoint, switched to Numelvi a couple of months ago, and so far it's working well.

Those are early signals, not conclusions. Numelvi's real-world dataset is months deep, not years. We don't have anything close to the decade of post-market data that backs Apoquel. If your vet suggests Numelvi, three questions are worth asking: Is this a better fit than Apoquel given my dog's specific bloodwork? What monitoring schedule do you want for the first six months? And what's the fallback if it doesn't hold?

Which medication for which situation

There's no single best allergy drug. There's the one that fits your dog's pattern, your dog's bloodwork, and your budget. Here's how most veterinary dermatologists I worked with at Angell would frame the decision.

First-time allergies, mild to moderate itch: Cytopoint or Befrena is often the first try. One injection, no daily pills, no systemic immune suppression. If it controls the itch for four to six weeks, you have a simple protocol. If it fades at two weeks or doesn't touch the itch at all, a JAK inhibitor is the next conversation.

Chronic or severe atopic dermatitis: Apoquel, Zenrelia, or Numelvi as daily oral maintenance. The itch is driven by multiple pathways, and JAK inhibition covers more of them than a single-cytokine antibody. Apoquel has the longest track record. Zenrelia is the move when Apoquel's side-effect profile is concerning. Numelvi is the newest option with the tightest selectivity and the thinnest safety dataset.

Dogs who've been on Apoquel and it's not holding: Two paths. If the itch control is good but the bloodwork is concerning (neutrophil decline, liver enzyme elevation), Zenrelia or Numelvi is the lateral move: same drug class, tighter selectivity. If Apoquel is losing effectiveness against the itch itself, Cytopoint or Befrena can be added alongside it, because they work through different mechanisms and can be used together.

Injection-phobic dogs or owners: Apoquel, Zenrelia, or Numelvi are all oral tablets. Cytopoint and Befrena both require a clinic visit for each injection.

Cost pressure: Do the monthly math. Apoquel at $2 to $4 per day runs $60 to $120 per month. Cytopoint at $50 to $150 every four to eight weeks can be cheaper for large dogs who hold the full duration, or more expensive for small dogs who need it every four weeks. Zenrelia pricing is comparable to Apoquel. Ask your clinic for the monthly number, not the per-dose number.

Breed-specific patterns worth knowing

Allergy medications aren't dosed by breed, but certain breeds show patterns that shape how the conversation goes. Plumb's Veterinary Drug Handbook, the reference most US vets keep on their desk, lists weight-based dosing for both oclacitinib and ilunocitinib. The breed patterns below affect which drug your vet reaches for, not how much.

French Bulldogs and English Bulldogs come with BOAS (brachycephalic obstructive airway syndrome, the breathing-structure issue that makes the face flat) and tend toward complex skin. Some owners report Apoquel making skin issues worse rather than better. These breeds often end up on combination protocols or rotating between Cytopoint and a JAK inhibitor seasonally.

Labrador Retrievers on long-term JAK inhibitors need liver and kidney monitoring on schedule. Labs are predisposed to weight gain and metabolic conditions, and adding immune modulation to that picture means the bloodwork panel every six months isn't optional.

West Highland White Terriers are the breed most dermatologists will tell you often needs combination therapy. Single-drug control of Westie skin disease is the exception, not the rule.

Cocker Spaniels with seasonal allergies sometimes land on a protocol that combines monthly Cytopoint injections from May through September with Apoquel for breakthrough itch, then nothing through winter. That seasonal approach reduces total drug exposure over the dog's lifetime.

Weimaraners can develop allergic dermatitis that moves fast. Open wounds within two weeks of a flare, even on Apoquel, is a pattern dermatologists see in this breed. If your Weimaraner is breaking through medication, don't wait for the recheck. Call the clinic.

What to track on any allergy medication

Whichever drug your vet chose, five things are worth logging between visits. This isn't busywork. It's what your vet actually reads at the recheck, and without it the conversation defaults to “seems better” or “I think it's getting worse,” neither of which gives the clinic enough to adjust the protocol.

First: symptom frequency and severity. How many times per day is the dog scratching, licking paws, or rubbing its face? A number beats an adjective. “Scratched six times today” tells the DVM more than “still itchy.”

Second: medication response time. After each dose or injection, how many hours until the scratching slows? If Cytopoint used to last six weeks and now fades at three, that's a pattern. If Apoquel used to quiet the itch within four hours and now takes twelve, that's worth noting.

Third: new lumps, skin infections, or GI changes. Any new lump on a dog taking a JAK inhibitor gets aspirated at the clinic. Recurring ear infections or hot spots suggest the immune suppression cost is adding up. Persistent soft stool or vomiting after the initial settling period deserves a call.

Fourth: seasonal pattern. Does the itch start in April and end in October? Or is it year-round? This distinction determines whether your dog needs seasonal or maintenance dosing and whether immunotherapy (allergy testing and desensitization) is worth pursuing.

Fifth: bloodwork schedule. For JAK inhibitors, a CBC (the red-and-white-cell count panel) before starting, again at three to six months, and then at least annually. The specific line to watch: neutrophils. A chemistry panel checking liver and kidney values gets added for senior dogs. The medication side-effect tracking page walks through how to keep these records organized between rechecks.

When medication alone isn't enough

Some dogs go through Apoquel, Zenrelia, Numelvi, Cytopoint, and Befrena and still scratch. That's the point where the conversation shifts to immunotherapy: intradermal allergy testing (injections under the skin that map exactly what the dog reacts to) followed by desensitization shots or sublingual drops tailored to those specific allergens.

Immunotherapy isn't fast. Most protocols take six to twelve months to show results, and success rates run around 60 to 80 percent in published studies. It's also the only approach that tries to retrain the immune response rather than block it. The Merck Veterinary Manual, the reference textbook clinicians use, calls allergen-specific immunotherapy the only treatment that can alter the underlying disease process in canine atopic dermatitis. That's the chapter I used to photocopy for the front desk when an owner asked why allergy shots take so long.

While immunotherapy ramps up, most dogs stay on a JAK inhibitor or Cytopoint for symptom control. The medications and immunotherapy aren't competitors. They're layers.

The conversation to have with your vet

Don't walk in asking for a specific drug by name. Walk in with your dog's pattern: when the itch started, what makes it worse, whether it's seasonal or year-round, what's been tried and how long it held. That gives the DVM enough to match the mechanism to the problem.

Three questions worth asking: What mechanism does this medication use, and why does it fit my dog's allergy pattern? What should I watch for between rechecks? And what does the monthly cost look like at my dog's weight?

The Apoquel deep-dive covers the side-effect profile, long-term safety data, and monitoring protocol for that specific drug. If your vet has already chosen Apoquel and you want to know what the ten-year data says, start there.

Questions about dog allergy medications

Five drugs. Two approaches. The right one depends on your dog's itch pattern, bloodwork, breed history, and budget. Track what changes between rechecks, bring the log to the clinic, and let your vet adjust the protocol with actual data instead of a guess. If the current medication isn't holding, that's a phone call, not a dose change at home.